Matt Phipps
Stock Analyst at William Blair
(1.96)
# 3,171
Out of 5,245 analysts
21
Total ratings
31.25%
Success rate
8.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Outperform | n/a | $2.07 | - | 1 | Jan 5, 2026 | |
| EVMN Evommune | Initiates: Outperform | n/a | $22.87 | - | 1 | Dec 1, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | n/a | $11.00 | - | 1 | Oct 16, 2025 | |
| INSM Insmed | Initiates: Outperform | n/a | $106.24 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $10.87 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $0.903 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $2.60 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $11.31 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $26.88 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $11.19 | - | 1 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.37 | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.13 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.84 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $59.46 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.52 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.86 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $193.76 | - | 2 | Jun 8, 2021 |
Compass Therapeutics
Jan 5, 2026
Initiates: Outperform
Price Target: n/a
Current: $2.07
Upside: -
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: n/a
Current: $22.87
Upside: -
Climb Bio
Oct 16, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.00
Upside: -
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $106.24
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $10.87
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.903
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.60
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.31
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $26.88
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.19
Upside: -
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.37
Upside: -
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.13
Upside: -
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $13.84
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $59.46
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.52
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.86
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $193.76
Upside: -